UK markets closed

Sutro Biopharma, Inc. (STRO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.9500+0.0400 (+0.81%)
At close: 04:00PM EST
4.9600 +0.01 (+0.20%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.9100
Open4.9400
Bid4.9500 x 900
Ask5.4800 x 800
Day's range4.9300 - 5.0800
52-week range2.0100 - 6.1100
Volume487,030
Avg. volume790,345
Market cap301.718M
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-2.9100
Earnings date28 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.67
  • Zacks

    Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

    Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • GlobeNewswire

    Sutro Biopharma to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences. Conference Details: Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDate: February 13-14, 2024Location: Virtual TD Cowen 44th Annual Health

  • GlobeNewswire

    Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

    Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα expression Promising clinical activity and tolerability of luvelta as both a monotherapy and in combination across multiple cancers may provide for a significant commercial opportunity Investor webcast today at 1:30 p.m. PT / 4:30 p.m. ET S